Handelsbanken Fonder AB Has $26.08 Million Position in Krystal Biotech, Inc. $KRYS

Handelsbanken Fonder AB increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 58.4% in the 4th quarter, Holdings Channel reports. The firm owned 105,800 shares of the company’s stock after purchasing an additional 39,000 shares during the period. Handelsbanken Fonder AB’s holdings in Krystal Biotech were worth $26,084,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KRYS. Profund Advisors LLC lifted its holdings in shares of Krystal Biotech by 18.7% during the fourth quarter. Profund Advisors LLC now owns 9,887 shares of the company’s stock worth $2,438,000 after buying an additional 1,557 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Krystal Biotech by 7.0% during the fourth quarter. ProShare Advisors LLC now owns 6,116 shares of the company’s stock worth $1,508,000 after buying an additional 399 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Krystal Biotech during the fourth quarter worth approximately $274,000. DNB Asset Management AS lifted its holdings in shares of Krystal Biotech by 31.3% during the fourth quarter. DNB Asset Management AS now owns 3,093 shares of the company’s stock worth $763,000 after buying an additional 737 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Krystal Biotech during the fourth quarter worth approximately $769,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 3.0%

Shares of NASDAQ KRYS opened at $302.05 on Thursday. The business has a fifty day simple moving average of $270.39 and a 200 day simple moving average of $256.01. The firm has a market capitalization of $8.90 billion, a price-to-earnings ratio of 40.38 and a beta of 0.50. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. On average, research analysts anticipate that Krystal Biotech, Inc. will post 7.98 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at $5,985,141.60. This represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the transaction, the insider owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 97,714 shares of company stock worth $26,183,109 over the last three months. 13.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating for the company. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Bank of America upped their target price on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Guggenheim upped their target price on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.